Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NDI-101150 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Nimbus Therapeutics

    • Most Recent Events

    • 04 Jun 2024 Results of dose-escalation/expansion data as of Dec 13, 2023, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 23 May 2024 According to a Nimbus Therapeutics media release, data from the study will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 June 4, 2024 in Chicago, IL.
    • 23 May 2024 Results (n=59,as of March 18, 2024) presented in the Nimbus Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top